- Home
- SSSS vs VTYX Comparison
SSSS vs VTYX Comparison
Compare SSSS & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSSS
- VTYX
- Stock Information
- Founded
- SSSS 2010
- VTYX 2018
- Country
- SSSS United States
- VTYX United States
- Employees
- SSSS N/A
- VTYX N/A
- Industry
- SSSS Finance: Consumer Services
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- SSSS Finance
- VTYX Health Care
- Exchange
- SSSS Nasdaq
- VTYX Nasdaq
- Market Cap
- SSSS 138.2M
- VTYX 154.9M
- IPO Year
- SSSS N/A
- VTYX 2021
- Fundamental
- Price
- SSSS $9.10
- VTYX $2.30
- Analyst Decision
- SSSS Strong Buy
- VTYX Buy
- Analyst Count
- SSSS 4
- VTYX 2
- Target Price
- SSSS $9.50
- VTYX $9.00
- AVG Volume (30 Days)
- SSSS 263.3K
- VTYX 429.2K
- Earning Date
- SSSS 11-06-2025
- VTYX 11-06-2025
- Dividend Yield
- SSSS 10.96%
- VTYX N/A
- EPS Growth
- SSSS N/A
- VTYX N/A
- EPS
- SSSS 2.22
- VTYX N/A
- Revenue
- SSSS $2,784,381.00
- VTYX N/A
- Revenue This Year
- SSSS $6.95
- VTYX N/A
- Revenue Next Year
- SSSS N/A
- VTYX N/A
- P/E Ratio
- SSSS $4.11
- VTYX N/A
- Revenue Growth
- SSSS N/A
- VTYX N/A
- 52 Week Low
- SSSS $3.77
- VTYX $0.78
- 52 Week High
- SSSS $9.50
- VTYX $3.39
- Technical
- Relative Strength Index (RSI)
- SSSS 64.23
- VTYX 39.52
- Support Level
- SSSS $8.63
- VTYX $2.31
- Resistance Level
- SSSS $8.75
- VTYX $2.54
- Average True Range (ATR)
- SSSS 0.17
- VTYX 0.14
- MACD
- SSSS 0.03
- VTYX -0.02
- Stochastic Oscillator
- SSSS 55.56
- VTYX 9.69
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.